Medtech Insight talked to Michael Bodner, the worldwide president of Johnson & Johnson/Biosense Webster, about the company’s plans to stay number one in the cardiac ablation market. In part 1 of the interview, the medtech veteran talked about the company's plan to compete in the crowded pulsed field ablation field.
Johnson & Johnson/Biosense Webster Inc is prepared to compete in the increasingly crowded pulsed field ablation (PFA) space, buttressing its Varipulse PFA system with leading radiofrequency ablation technology and advanced cardiac mapping systems.
The J&J subsidiary helped create the field of electrophysiology when it introduced the world’s first irrigated ablation catheter in 1998 and has continued to advance catheter-ablation and mapping technology ever...
A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.
A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.
Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.
